GILD34 Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
Gilead Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$173.25 |
52 Week High | US$215.96 |
52 Week Low | US$164.46 |
Beta | 0.20 |
1 Month Change | -5.69% |
3 Month Change | -10.71% |
1 Year Change | -18.72% |
3 Year Change | -2.72% |
5 Year Change | 35.69% |
Change since IPO | -4.17% |
Recent News & Updates
Recent updates
Shareholder Returns
GILD34 | BR Biotechs | BR Market | |
---|---|---|---|
7D | -2.3% | -3.0% | -1.0% |
1Y | -18.7% | -9.0% | 13.1% |
Return vs Industry: GILD34 underperformed the BR Biotechs industry which returned -9% over the past year.
Return vs Market: GILD34 underperformed the BR Market which returned 13.1% over the past year.
Price Volatility
GILD34 volatility | |
---|---|
GILD34 Average Weekly Movement | 2.7% |
Biotechs Industry Average Movement | 9.4% |
Market Average Movement | 4.6% |
10% most volatile stocks in BR Market | 8.7% |
10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: GILD34 has not had significant price volatility in the past 3 months.
Volatility Over Time: GILD34's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
GILD34 fundamental statistics | |
---|---|
Market cap | R$431.60b |
Earnings (TTM) | R$29.29b |
Revenue (TTM) | R$140.18b |
14.7x
P/E Ratio3.1x
P/S RatioIs GILD34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GILD34 income statement (TTM) | |
---|---|
Revenue | US$27.12b |
Cost of Revenue | US$6.02b |
Gross Profit | US$21.10b |
Other Expenses | US$15.43b |
Earnings | US$5.67b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | 4.54 |
Gross Margin | 77.80% |
Net Profit Margin | 20.89% |
Debt/Equity Ratio | 109.8% |
How did GILD34 perform over the long term?
See historical performance and comparison